Clinical Trial: Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome
Study Status: Enrolling by invitation
Recruit Status: Unknown status
Study Type: Interventional
Official Title: Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome
Brief Summary: Purpose:Retinopathy of prematurity (ROP) continues tobe a major cause of blindness in children. Although ablation of the retina with laser or cryotherapy reduces the incidence of blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are often poor. Vascular endothelial growth factor(VEGF) has an important role in the pathogenesis of ROP and inhibition of VEGF expression in the neovascular phase might prevent destructive neovascularization in ROP. The aim of this study is to determine the safety and efficacy of intravitreal bevacizumab in the treatment of retinopathy of prematurity
Detailed Summary:
Sponsor: Asociación para Evitar la Ceguera en México
Current Primary Outcome: Clinical appearance
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Asociación para Evitar la Ceguera en México
Dates:
Date Received: June 29, 2006
Date Started: July 2006
Date Completion: November 2006
Last Updated: June 28, 2009
Last Verified: June 2006